THANK YOU FOR SUBSCRIBING
Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Tech Outlook
Tracy Vandenbroek, Senior Director, Marketing & Strategy, Sysmex Inostics“Our customers need a trusted testing partner, and they expect their results back quickly. We win customers due to our long-standing history within the pharmaceutical space and our nimble nature,” says Tracy Vandenbroek, senior director, marketing and strategy, Sysmex Inostics.
Sysmex Inostics believes that in the fight against cancer, spanning basic research and drug development to patient care, every decision counts, every patient counts, and every molecule counts. When it comes to fighting cacner, the details change lives. From research to treatment to livelihood, the company is enabling decision-making on an individual level. This has been possible due to its world-class CLIA lab and ultrasensitive cfDNA technology, complemented by an excellent team with a profound customer focus and a passion for discovery.
Simultaneously, its CDx partnership with QIAGEN is a bonus to the pharma clients as this provides a clear path to CDx regulatory clearance and commercialization.
The outcome of Kathy’s illness may have been different today. Because of advancements in immune-oncology (I/O) boosted by ultra-sensitive liquid biopsy testing, more patients survive cancer these days. On January 12, 2023, CNN reported, “the U.S. cancer death rate has fallen 33 percent since 1991, which corresponds to an estimated 3.8 million deaths averted.”
“At Sysmex Inostics, we are here for our loved ones who have survived or lost their cancer battles. We are tired of a diagnosis defining people’s livelihood, so we propel our knowledge forward to inform effective treatment — helping patients live their lives better for longer,” says Vandenbroek.
Vandenbroek, in this regard recalls the story of Kathy, a friend, and one of the sharpest breast cancer researchers Vandenbroek has met. She lost her battle with a rare case of AML ten years ago after multiple rounds of radiation and chemo, a stem cell transplant, and partook in several “angel drug” trials.
Our customers need a trusted testing partner, and they expect their results back quickly. We win customers due to our longstanding history within the pharmaceutical space and our nimble nature.
The outcome of Kathy’s illness may have been different today. Because of advancements in immune-oncology (I/O) boosted by ultra-sensitive liquid biopsy testing, more patients survive cancer these days. On January 12, 2023, CNN reported, “the U.S. cancer death rate has fallen 33 percent since 1991, which corresponds to an estimated 3.8 million deaths averted.”
As of 2022, patients afflicted with AML have an I/O called Ivosidenib to help them fight this evasive cancer. Vandenbroek is proud of this advancement because the OncoBeam version of the AML-SEQ panel was used in the clinical trial that produced it.
“Just imagine if I/O drugs were available in 2013. Just imagine if Kathy was still alive fighting the good fight against breast cancer in the lab. It’s personal to all of us at Sysmex Inostics,” she says.
Company
Sysmex Inostics
Management
Tracy Vandenbroek, Senior Director, Marketing & Strategy, Sysmex Inostics
Description
Sysmex Inostics has played a significant role in cancer discoveries within the pharmaceutical, clinical, and research communities. Today, with its CLIA-validated next generation sequencing (NGS) Plasma-Safe-SeqS (PSS) technology testing services, the company empowers more accurate detection of low-frequency biomarkers.
Sysmex Inostics News
Sysmex Inostics’ RAS-RAF-SEQ Assay Receives New York State Department of Health CLEP Approval for Use in Clinical Trials
“NY State CLEP approval for RAS-RAF-SEQ will provide pharma and clinical trial investigators who want to test samples from the New York State with a non-invasive tool to uncover deeper insights in assessing novel therapies for various RAS-RAF and/or PI3K-associated cancers,” said Shinichi Sato, President, and CEO of Sysmex Inostics. “This approval shows our commitment in expanding access of our ultrasensitive assays to all patients fighting cancer with liquid biopsy services that are compliant with clinical regulations.”
Genetic mutations along the RAS-RAF pathway (KRAS, NRAS, BRAF) are common across numerous cancer types, and often play a significant role in cancer development, progression, as well as treatment resistance.1-3 Following initial diagnosis, understanding a patient’s specific genomic alterations along the RAS-RAF pathway helps inform therapy selection, monitor treatment response, and identify emerging resistance. Moreover, mutations in the PI3K pathway (PIK3CA, AKT1) are known to modulate signaling through the RAS-RAF pathway and may provide additional information to guide therapeutic decision-making.1-3 The RAS-RAF-SEQ panel tracks key mutations in the RAS-RAF and PI3K pathways with maximum efficiency for optimizing therapy, avoiding over-treatment, and maximizing quality of life during treatment.
Plasma-Safe-SeqS technology utilized in the RAS-RAF-SEQ assay is expertly designed to preserve all input molecules for analysis, leading to ultrasensitive detection of low-level genomic mutations. “The RAS-RAF-SEQ assay achieves ultra-sensitivity, while maintaining robust specificity for the targeted mutations in RAS-RAF or PI3K signaling pathway,” said Jonathan Craft, Associate Director, Translational Research, Sysmex Inostics.